[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastroesophageal-varices\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastroesophageal-varices":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,67],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100429121","development-of-4d-flow-mri-for-risk-stratification-of-variceal-bleeding-in-cirrhosis-100429121",false,"NCT04867954","Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis","Inclusion Criteria for Aim 1:\n\n* Healthy volunteers: Adults (\\>18 years) with no known liver pathology\n* Obese volunteers: Adults (\\>18 years), no known liver pathology, body mass index (BMI) ≥ 35\n* Patients: Adults (\\>18 years) with known cirrhosis and known Gastroesophageal varices\n\nExclusion Criteria for Aim 1:\n\n* contraindications to MRI\n* hypersensitivity reactions to both contrast agents\n* patients with recent treatment for varices with embolization, TIPS, or other endovascular treatment\n* patients with active GEV bleeding; known occlusive thrombus in portal vein, splenic vein, or superior mesenteric vein.\n* patients with large HCC with known PC involvement.\n\nInclusion criteria for Aim 2-4:\n\n* Adults (\\>18 years) with known cirrhosis\n\nExclusion Criteria for Aim 2-4:\n\n* Contraindications to MRI\n* Recent treatment (\\\u003C 1 year) for varices\n* Known occlusive thrombus in portal vein; splenic vein, or superior mesenteric vein\n* Large hepatocellular carcinoma (HCC) with known PV involvement\n* Hypersensitivity reactions to both contrast agents\n* Participants requiring conscious sedation for imaging are not eligible; participants requiring mild, oral anxiolytics for the clinical MRI scan will be allowed to participate as long as the following criteria are met:\n\n  * The participant has their own prescription for the medication\n  * The informed consent process is conducted prior to the self-administration of the medication.\n  * The participant comes to the research visit with a driver.\n\nInclusion Criteria for Aim 5:\n\n* Adults (\\>18 years) with Fontan repair and diagnosed FALD\n\nExclusion Criteria for Aim 5:\n\n* Contraindications to MRI\n* Recent treatment (\\\u003C 1 year) for varices\n* Known occlusive thrombus in portal vein; splenic vein, or superior mesenteric vein\n* Large hepatocellular carcinoma (HCC) with known PV involvement\n* Hypersensitivity reactions to both contrast agents\n* Participants requiring conscious sedation for imaging are not eligible; participants requiring mild, oral anxiolytics for the clinical MRI scan will be allowed to participate as long as the following criteria are met:\n\n  * The participant has their own prescription for the medication\n  * The informed consent process is conducted prior to the self-administration of the medication.\n  * The participant comes to the research visit with a driver.",true,"ALL","18 Years",{"count":19,"type":20},146,"ESTIMATED","OBSERVATIONAL","The goal of this research is to validate novel non-invasive Magnetic resonance imaging (MRI) biomarkers to detect Gastroesophageal varices (GEV) in patients with cirrhosis, including fractional flow change in the portal vein and elevated azygos flow.\n\nEnd-stage liver disease (cirrhosis) is characterized by advanced fibrosis, liver failure, and portal hypertension. There are many causes of cirrhosis, including viral hepatitis, alcohol abuse, and perhaps most importantly, non-alcoholic fatty liver disease (NAFLD) and its aggressive subset, non-alcoholic steatohepatitis (NASH). 3 million new cases of end-stage liver disease (cirrhosis) are expected over the next decade. In cirrhosis, portosystemic collaterals that shunt blood away from the liver develop due to increased portal pressure. Gastroesophageal varices (GEV) are the most clinically relevant because they can cause fatal internal bleeding. GEV bleeding carries \\~20% mortality at 6 weeks, and \\~34% overall mortality. Identification of at-risk varices, prior to bleeding, is of paramount importance to initiate primary prophylaxis. To identify and treat at-risk patients, current guidelines recommend regular esophagogastroduodenoscopy (EGD) and variceal band ligation. Detection of high-risk GEV is key to initiating primary prophylaxis, which can reduce mortality by 50-70%.\n\nHowever, endoscopy is invasive and often unnecessary when no treatment is required. Therefore, the American Association for the Study of Liver Diseases has identified the development of \"non-invasive markers that predict the presence of high-risk varices\" as a major unmet need.",[24,25,26],"Cirrhosis, Liver","Gastroesophageal Varices","Fontan Procedure","RECRUITING","2026-04-07",{"date":30,"type":31},"2026-04-09","ACTUAL",{"date":33,"type":31},"2021-10-28",{"date":35,"type":20},"2026-06-30",{"name":37,"class":38},"University of Wisconsin, Madison","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":50,"conditions":51,"keywords":54,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":39},"100624139","cirrhotic-and-non-cirrhotic-patients-with-clinically-significant-portal-hypertension-100624139","NCT07405749","Cirrhotic and Non-cirrhotic Patients With Clinically Significant Portal Hypertension","Incidence and Predictive Factors of Elective Procedure-Related Bleeding in Cirrhotic and Non-Cirrhotic Patients With Clinically Significant Portal Hypertension","PREDIBLEED","Inclusion Criteria:\n\n* Age \\> 18 years;\n* Ability to provide informed consent;\n* Specific signs of CSPH (gastroesophageal varices, porto-systemic collaterals, liver stiffness measurement (LSM) \\> 25 KPa or spleen stiffness measurement (SSM) \\> 50 KPa);\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years;\n* Life expectancy \\\u003C 6 months;\n* Patients unable to sign informed consent.",{"count":49,"type":20},2500,"Alterations in conventional coagulation tests in patients with cirrhosis and\u002For portal hypertension do not reliably predict bleeding risk, as hemostatic balance is complex and often compensated. Many procedure-related bleeding events are driven by non-coagulatory factors, such as portal hypertension or technical aspects of the procedure. Most commonly performed procedures carry a low risk of bleeding even in the presence of elevated INR or thrombocytopenia, and no validated laboratory thresholds support prophylactic correction. Risk assessment should therefore be based on procedural factors, severity of liver disease, and systemic patient conditions, with correction of modifiable risk factors particularly before high-risk elective procedures.",[24,52,53,25],"Portal Hypertension","Clinically Significant Portal Hypertension(CSPH)",[55,56],"Thrombotic events","porto-systemic collaterals","NOT_YET_RECRUITING","2026-02-05",{"date":60,"type":31},"2026-02-12",{"date":62,"type":20},"2026-02",{"date":64,"type":20},"2030-02",{"name":66,"class":38},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":4},"100602894","feasibility-and-safety-evaluation-of-endoscopic-treatment-of-esophagogastric-varices-in-cirrhosis-on-the-day-care-unit-100602894","NCT07129447","Feasibility and Safety Evaluation of Endoscopic Treatment of Esophagogastric Varices in Cirrhosis on the Day-care Unit","Feasibility and Safety Assessment of Endoscopic Treatment of Esophagogastric Variceal Bleeding in Cirrhosis on the Day Unit: a Single-centre, Prospective-historical Controlled Study","Inclusion Criteria:\n\n1. aged 18-75 years;\n2. diagnosis of cirrhosis and portal hypertension by clinical manifestations, laboratory tests, imaging tests and histologic examinations;\n3. gastroscopic grading of esophagogastric varices as moderate or severe;\n4. no ruptured esophagogastric varices bleeding in the last 5 days;\n5. endoscopic treatment of esophagogastric varices during hospitalization.\n\nExclusion Criteria:\n\n1. first endoscopic treatment of esophagogastric varices;\n2. this is an acute esophagogastric variceal rupture and bleeding;\n3. previous TIPS or liver transplantation;\n4. isolated fundal varices or ectopic varices;\n5. primary hepatocellular carcinoma or acute or chronic hepatic failure, Child-pugh class C, hepatic encephalopathy stage 2 or higher;\n6. spontaneous abnormally large shunts, uncontrolled infections and sepsis, uncontrolled hypertension;\n7. combined cardiac, pulmonary, cerebral, renal and other serious complications or other reasons for not being able to tolerate the examination;\n8. pregnant women and lactating women;\n9. failure to sign the informed consent or refusal to participate.","75 Years",{"count":76,"type":20},330,"The goal of this observational study is to learn about the feasibility and safety evaluation of endoscopic treatment of esophagogastric varices in cirrhosis on the day-care ward. The main question it aims to answer is:\n\nIs inpatient endoscopic treatment on day wards also feasible and safe for patients with esophagogastric variceal bleeding in cirrhosis when compared to inpatient endoscopy on a general ward? Participants undergoing inpatient endoscopic treatment for cirrhotic esophagogastric variceal bleeding on day wards and general wards will answer online survey questions about their postoperative period over a 1-year period.",[79,25],"Liver Cirrhosis",[81,82,83,84,85],"Esophagogastric variceal bleeding","Liver cirrhosis","Endoscopic therapy","Day ward","Variceal rebleeding","2025-08-11",{"date":88,"type":31},"2025-08-19",{"date":90,"type":20},"2025-09-01",{"date":92,"type":20},"2029-12-30",{"name":94,"class":38},"Qilu Hospital of Shandong University"]